Neuropore Therapies, Inc. is a biopharmaceutical company founded in 2008 by Professor Eliezer Masliah and colleagues from University of California at San Diego. We are committed to the discovery and development of disease modifying treatments for Parkinson’s Disease, Alzheimer’s Disease, and other neuro-degenerative disorders.
Based in the biotech hub of San Diego, the in-house expertise of our people and our global collaborations with academic and industry partners allow us to discover novel therapeutic targets and develop innovative therapeutics.
Our lead molecule for Parkinson’s Disease was partnered and entered into clinical development in 2015.
Our current pipeline also includes products that target multiple molecular mechanisms to facilitate the clearance of misfolded proteins.